Heathcare Software aids in radiology dose management.
Share:
Press Release Summary:
Certegra® Workstation promotes time conservation via suite of CT Contrast Dose Management(TM) applications and P3T® 2.0 operating environment. Informatics-driven touchscreen hub lets radiology technologists provide improved patient care from study setup and preparation to administration. In establishing and uploading patient's contrast-injection record, solution imports patient data directly from Modality Work List. This in turn reduces manual entry errors to patient record.
Original Press Release:
Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions
Powerful New Certegra® Informatics Workstation launched at SIIM 2012
Intended for U.S. Media Only
TARRYTOWN, N.Y. -- Bayer Radiology & Interventional announced the introduction of the Certegra® Workstation, an informatics-driven, touch-screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T® 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.
The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List - reducing manual entry errors to the patient record.
"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."
Interfacing with Medrad Stellant® CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care - enabling benefits including:
-- Reduce sub-diagnostic studies, unnecessary rescans and associated radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac and pulmonary angiography studies)
-- Enable more complete diagnostic decisions (PACS Outbound Interface)
-- Speed-up radiology report turnaround time and create greater study-volume bandwidth (RIS and SR Outbound Interfaces)
-- Improve department performance by trending, reporting and analyzing actionable data with pinpoint accuracy (Informatics Starter Package, and the Data Analysis and Reporting Tool) Bayer HealthCare will have the Certegra® Workstation on display at its booth at SIIM 2012 (booth #217 - 221).
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
[1] Reference on file.
[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.
[3] 510(k) FDA clearance number: K082905
CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com
